Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
AstraZeneca, breast cancer
AstraZeneca's experimental drug disappoints in breast cancer survival trial
AstraZeneca said on Monday its experimental precision drug developed with Japan's Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
AstraZeneca, Daiichi's Trodelvy rival fails to improve overall survival in breast cancer trial
AstraZeneca and Daiichi Sankyo’s TROP2-directed antibody-drug conjugate (ADC) has again failed to improve overall survival (OS) in a phase 3 trial. The latest miss happened in breast cancer, a setting in which Gilead’s rival Trodelvy significantly improved OS in a prior late-phase study.
AstraZeneca drug fails to extend lives of breast cancer patients
A new AstraZeneca drug has failed to extend significantly the lives of breast cancer patients in a blow to the company’s ambitions to hit an $80bn revenue target by 2030.
AstraZeneca's experimental cancer drug shows no significant improvement in overall survival
AstraZeneca said on Monday its experimental precision drug developed with Daiichi Sankyo did not significantly improve overall survival for patients with a type of breast cancer in a late-stage trial.
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients
AstraZeneca released results from the TROPION-Breast01 Phase 3 trial of datopotamab deruxtecan, showing no statistically significant improvement in overall survival. The trial met its progression-free survival endpoint,
AstraZeneca and Daiichi Suffer New Setback With Mixed Breast Cancer Drug Results
AstraZeneca Plc said an experimental cancer drug it’s developing with Daiichi Sankyo Co. did not help breast cancer patients live longer than chemotherapy.
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
AstraZeneca stock slumped Monday after its Daiichi Sankyo-partnered drug missed its mark in a study of patients with breast cancer.
AstraZeneca and Daiichi Sankyo report data from Phase III breast cancer trial
AstraZeneca and Daiichi Sankyo have reported results from the TROPION-Breast01 Phase III clinical trial of datopotamab deruxtecan (Dato-DXd) for breast cancer. The trial compared Dato-DXd to the investigator's choice of chemotherapy in patients with inoperable or metastatic hormone receptor (HR)-positive,
26m
AstraZeneca: Buy This Big Pharma Stock At A Discount Now
AstraZeneca topped the analyst consensus for net revenue and matched the analyst consensus for core EPS in Q2. See why I ...
cnbctv18
2h
AstraZeneca shares rally 13%, hit record high as firm gets nod for cancer drug
Astrazeneca Pharma India has received CDSO's (Central Drugs Standard Control Organisation) nod for the import of Durvalumab ...
15h
AstraZeneca PLC ADR underperforms Monday when compared to competitors
The AstraZeneca PLC ADR AZN slipped 1.58% to $77.14 Monday, on what proved to be an all-around great trading session for the ...
2h
EMA CHMP recommends AstraZeneca’s Fasenra to treat EGPA
Committee for Medicinal Products for Human Use (CHMP) has recommended approving AstraZeneca’s Fasenra (benralizumab) to treat ...
20h
Black Diamond Therapeutics' Lead Drug Candidate Shows Initial Anti-tumor Activity In Certain Type Of Lung Cancer Resistant To AstraZeneca's Drug
Black Diamond Therapeutics reports promising initial Phase 2 data for BDTX-1535 in relapsed EGFR-mutant NSCLC patients. With ...
20h
AstraZeneca falls Monday, underperforms market
AstraZeneca PLC AZN shares dropped 1.66% to £115.84 Monday, on what proved to be an all-around great trading session for the ...
sinchew
1h
AstraZeneca earns 3 different workplace certifications across its operations in North Africa and Levant in 2024
AstraZeneca, a global leader in the pharmaceutical and biotechnology sector, has been recognized with three prestigious ...
Daily
5h
Lung cancer drug: AstraZeneca India wins CDSCO nod for Durvalumab for specified additional indication
Bengaluru: AstraZeneca Pharma India Limited has received permission to import for sale and distribution of Durvalumab 120 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
FluMist
Dow Jones Industrial Average
Trade
Daiichi Sankyo
Food and Drug Administration
Feedback